THE RELATIONSHIP of trichophytosis and peripheral vascular disease has been discussed by various authors.1 Studies1a were made which showed that a high percentage (93 per cent) of patients with thromboangiitis obliterans had clinical trichophytosis while only 73 per cent of the controls had clinical trichophytosis. Naide1a showed that four times as many patients with thromboangiitis obliterans gave positive cutaneous reactions to trichophytin as those without the disorder. Migratory phlebitis as a result of trichophytosis is well known, and "vascular trichophytids"2 are also recognized.
As far as I can find, the use of trichophytin in the treatment of thromboangiitis obliterans or migratory phlebitis has not been carried on to any extent. During the last year, I have seen 2 patients with thromboangiitis obliterans whose response following the use of trichophytin was so dramatic that I feel that some attention should be given again to the possibility of
HOLMAN JC. USE OF TRICHOPHYTIN IN THROMBOANGIITIS OBLITERANS. Arch Derm Syphilol. 1947;55(4):512–513. doi:10.1001/archderm.1947.01520040081008
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: